Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 181.00
+3.00 (1.69%)
Last updated: Dec 1, 2025, 8:19 AM CET
Ascendis Pharma Company Description
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ascendis Pharma A/S
| Country | Denmark |
| Founded | 2006 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 1,017 |
| CEO | Jan Mikkelsen |
Contact Details
Address: Tuborg Boulevard 12 Hellerup, 2900 Denmark | |
| Phone | 45 70 22 22 44 |
| Website | ascendispharma.com |
Stock Details
| Ticker Symbol | A71 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jan Mikkelsen | Chief Executive Officer |
| Scott Smith | Chief Financial Officer |
| Chad Fugure | Head of Investor Relations |